2024-03-25 13:07:32 ET
Summary
- M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products.
- The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027.
- Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
On Tuesday, I posted an article around three biotech/biopharma mid-cap concerns that make logical buyout targets for larger players in the pharma space. As noted in the previous article, there are many reasons to believe the M&A will remain active in this sector. Among these are the huge amounts of cash on the balance sheets of major drug firms, some key patent expirations over the next few years, and dramatically dropping revenue from Covid-related products like vaccines and therapeutics....
Read the full article on Seeking Alpha
For further details see:
2 More Potential Biotech Buyout Targets